Cargando…
Efficacy Evaluation of a Bivalent Vaccine Containing Porcine Circovirus Type 2b and Mycoplasma hyopneumoniae Against an Experimental Dual Challenge
The purpose of this study was to evaluate the efficacy of a new, single-dose bivalent vaccine containing porcine circovirus type 2b (PCV2b) and Mycoplasma hyopneumoniae against a dual PCV2b and M. hyopneumoniae challenge. At −25 days post challenge (dpc, 10 days of age), one pig group (designated as...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119751/ https://www.ncbi.nlm.nih.gov/pubmed/33996979 http://dx.doi.org/10.3389/fvets.2021.652313 |
_version_ | 1783691920010117120 |
---|---|
author | Ahn, Yongjun Yang, Siyeon Oh, Taehwan Park, Kee Hwan Cho, Hyejean Suh, Jeongmin Chae, Chanhee |
author_facet | Ahn, Yongjun Yang, Siyeon Oh, Taehwan Park, Kee Hwan Cho, Hyejean Suh, Jeongmin Chae, Chanhee |
author_sort | Ahn, Yongjun |
collection | PubMed |
description | The purpose of this study was to evaluate the efficacy of a new, single-dose bivalent vaccine containing porcine circovirus type 2b (PCV2b) and Mycoplasma hyopneumoniae against a dual PCV2b and M. hyopneumoniae challenge. At −25 days post challenge (dpc, 10 days of age), one pig group (designated as the vaccinated/challenged group) received a single, 1.0 ml dose of bivalent vaccine. Pigs in both the vaccinated/challenged and unvaccinated/challenged groups were then inoculated intranasally with PCV2b and M. hyopneumoniae at 0 dpc (35 days of age). Pigs in vaccinated/challenged group induced significantly higher levels of neutralizing antibodies against PCV2b and cell-mediated immunity against PCV2b and M. hyopneumonia when compared with pigs in unvaccinated/challenged group. The vaccination of pigs with a bivalent vaccine also reduced PCV2b viremia, reduced mycoplasmal nasal shedding, and decreased the severity of both lung and lymphoid lesions for PCV2b and M. hyopneumoniae infection, respectively. The results of this study demonstrated that the evaluated bivalent vaccine was effective in protecting pigs against PCV2b and M. hyopneumoniae infection. |
format | Online Article Text |
id | pubmed-8119751 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81197512021-05-15 Efficacy Evaluation of a Bivalent Vaccine Containing Porcine Circovirus Type 2b and Mycoplasma hyopneumoniae Against an Experimental Dual Challenge Ahn, Yongjun Yang, Siyeon Oh, Taehwan Park, Kee Hwan Cho, Hyejean Suh, Jeongmin Chae, Chanhee Front Vet Sci Veterinary Science The purpose of this study was to evaluate the efficacy of a new, single-dose bivalent vaccine containing porcine circovirus type 2b (PCV2b) and Mycoplasma hyopneumoniae against a dual PCV2b and M. hyopneumoniae challenge. At −25 days post challenge (dpc, 10 days of age), one pig group (designated as the vaccinated/challenged group) received a single, 1.0 ml dose of bivalent vaccine. Pigs in both the vaccinated/challenged and unvaccinated/challenged groups were then inoculated intranasally with PCV2b and M. hyopneumoniae at 0 dpc (35 days of age). Pigs in vaccinated/challenged group induced significantly higher levels of neutralizing antibodies against PCV2b and cell-mediated immunity against PCV2b and M. hyopneumonia when compared with pigs in unvaccinated/challenged group. The vaccination of pigs with a bivalent vaccine also reduced PCV2b viremia, reduced mycoplasmal nasal shedding, and decreased the severity of both lung and lymphoid lesions for PCV2b and M. hyopneumoniae infection, respectively. The results of this study demonstrated that the evaluated bivalent vaccine was effective in protecting pigs against PCV2b and M. hyopneumoniae infection. Frontiers Media S.A. 2021-04-30 /pmc/articles/PMC8119751/ /pubmed/33996979 http://dx.doi.org/10.3389/fvets.2021.652313 Text en Copyright © 2021 Ahn, Yang, Oh, Park, Cho, Suh and Chae. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Veterinary Science Ahn, Yongjun Yang, Siyeon Oh, Taehwan Park, Kee Hwan Cho, Hyejean Suh, Jeongmin Chae, Chanhee Efficacy Evaluation of a Bivalent Vaccine Containing Porcine Circovirus Type 2b and Mycoplasma hyopneumoniae Against an Experimental Dual Challenge |
title | Efficacy Evaluation of a Bivalent Vaccine Containing Porcine Circovirus Type 2b and Mycoplasma hyopneumoniae Against an Experimental Dual Challenge |
title_full | Efficacy Evaluation of a Bivalent Vaccine Containing Porcine Circovirus Type 2b and Mycoplasma hyopneumoniae Against an Experimental Dual Challenge |
title_fullStr | Efficacy Evaluation of a Bivalent Vaccine Containing Porcine Circovirus Type 2b and Mycoplasma hyopneumoniae Against an Experimental Dual Challenge |
title_full_unstemmed | Efficacy Evaluation of a Bivalent Vaccine Containing Porcine Circovirus Type 2b and Mycoplasma hyopneumoniae Against an Experimental Dual Challenge |
title_short | Efficacy Evaluation of a Bivalent Vaccine Containing Porcine Circovirus Type 2b and Mycoplasma hyopneumoniae Against an Experimental Dual Challenge |
title_sort | efficacy evaluation of a bivalent vaccine containing porcine circovirus type 2b and mycoplasma hyopneumoniae against an experimental dual challenge |
topic | Veterinary Science |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119751/ https://www.ncbi.nlm.nih.gov/pubmed/33996979 http://dx.doi.org/10.3389/fvets.2021.652313 |
work_keys_str_mv | AT ahnyongjun efficacyevaluationofabivalentvaccinecontainingporcinecircovirustype2bandmycoplasmahyopneumoniaeagainstanexperimentaldualchallenge AT yangsiyeon efficacyevaluationofabivalentvaccinecontainingporcinecircovirustype2bandmycoplasmahyopneumoniaeagainstanexperimentaldualchallenge AT ohtaehwan efficacyevaluationofabivalentvaccinecontainingporcinecircovirustype2bandmycoplasmahyopneumoniaeagainstanexperimentaldualchallenge AT parkkeehwan efficacyevaluationofabivalentvaccinecontainingporcinecircovirustype2bandmycoplasmahyopneumoniaeagainstanexperimentaldualchallenge AT chohyejean efficacyevaluationofabivalentvaccinecontainingporcinecircovirustype2bandmycoplasmahyopneumoniaeagainstanexperimentaldualchallenge AT suhjeongmin efficacyevaluationofabivalentvaccinecontainingporcinecircovirustype2bandmycoplasmahyopneumoniaeagainstanexperimentaldualchallenge AT chaechanhee efficacyevaluationofabivalentvaccinecontainingporcinecircovirustype2bandmycoplasmahyopneumoniaeagainstanexperimentaldualchallenge |